UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                   FORM 10-QSB

               QUARTERLY REPORT PURSUANT TO SECTIOIN 13 OR 15 (d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934


                       FOR THE PERIOD ENDED: JULY 31, 2003

                        COMMISSION FILE NUMBER: 000-31727


                       TRANSFORM PACK INTERNATIONAL, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

                  MINNESOTA                              41-1886254
      ------------------------------                 -------------------
      State or other jurisdiction of                 (IRS Employer
      incorporation or organization)                 Identification No.)


            12230 Forest Hill Blvd., Suite 157, Wellington, FL 33414
          -------------------------------------------------------------
          (Address, including zip code, of principal executive offices)

                                 (561) 227-1597
              ----------------------------------------------------
              (Registrant's telephone number, including area code)


  Indicate by check mark whether the registrant (1) has filed all documents and
 reports required to be filed by Sections 13 or 15(d) of the Securities Exchange
 Act of 1934 during the preceding 12 months (or for such shorter period that the
 registrant was required to file such reports), and (2) has been subject to such
                          filings for the past 90 days.

                                  YES X    NO ___

                      APPLICABLE ONLY TO CORPORATE ISSUERS:

         As of September 19, 2003, the number of the Company's shares of
            par value $.004 common stock outstanding was 32,968,957.


<PAGE>



                                      INDEX




   Part I - FINANCIAL INFORMATION

   Item 1 - Financial Statements-Unaudited

           Condensed Balance Sheet                                             3

           Condensed Statements of Operations                                  4

           Condensed Statement of Changes in Deficiency in Assets              5

           Condensed Statements of Cash Flows                                  6

           Notes to Condensed Consolidated Financial Statements                7

   Item 2- Management's Discussion and Analysis of Financial Condition
           And Results of Operations                                          11

   Item 3- Controls and Procedures                                            13


   PART II - OTHER INFORMATION                                                13


   SIGNATURES                                                                 14

                                       2

<PAGE>


PART I

ITEM 1.  FINANCIAL INFORMATION.



                       Transform Pack International, Inc.
                             Condensed Balance Sheet
                        (A Development Stage Enterprise)
                                  July 31, 2003
                                   (unaudited)

ASSETS

Current assets:
       Cash                                                           $   4,759
                                                                      ----------
       Total current assets                                               4,759

Property and equipment, net of accumulated
  depreciation of $2,597                                                  1,263
Other assets                                                             12,523
                                                                      ----------

Total assets                                                          $  18,545
                                                                      ==========


LIABILITIES AND SHAREHOLDERS' DEFICIT

Current liabilities:
       Accounts payable and accrued liabilities                       $ 236,761
       Notes payable - shareholder                                      183,612
                                                                      ----------

Total current liabilities                                               420,373


Commitments and contingencies


Deficiency in assets                                                   (401,828)
                                                                      ----------

Total liabilities and deficiency in assets                            $  18,545
                                                                      ==========










            See accompanying notes to condensed financial statements.

                                       3

<PAGE>



                       Transform Pack International, Inc.
                        Condensed Statement of Operations
                        ( A Development Stage Enterprise)
                  For the Periods Ended July 31, 2003 and 2002
                                   (unaudited)

<TABLE>
<CAPTION>
                                                                           For the
                                                                            period
                                                                           July 24,
                           For the three months    For the nine months       2001
                                  ended                  ended            (inception)
                          ----------------------  ----------------------      to
                           July 31,    July 31,    July 31,    July 31,    July 31,
                             2003        2002        2003        2002        2003
                          ----------  ----------  ----------  ----------  ----------
<S>                       <C>         <C>         <C>         <C>         <C>
Expenses Representing
  Net Loss                $   71,569  $   21,870  $  131,000  $   70,004  $  344,976
                          ==========  ==========  ==========  ==========  ==========










Basic and diluted
  loss per common share   $    0.002  $    0.001  $    0.005  $    0.003  $    0.013
                          ==========  ==========  ==========  ==========  ==========


Weighted average
  number of common shares
  outstanding             30,632,861  27,000,000  28,345,100  27,000,000  27,497,578
                          ==========  ==========  ==========  ==========  ==========
</TABLE>












            See accompanying notes to condensed financial statements.

                                       4

<PAGE>



                       Transform Pack International, Inc.
             Condensed Statement of Changes in Deficiency in Assets
                                  July 31, 2003
                                   (unaudited)

                              Common Stock
                             par value $.004
                                per share
                                40,000,000
                                authorized      Additional
                           --------------------  Paid-in   Accumulated  Total
                           # of Shares  Amount   Capital    Deficit     Equity
                           ----------- -------- ---------- ---------- ----------

Balance 7/24/01 (inception) 27,000,000 $108,000 $ (88,000) $       -  $  20,000

Net loss                             -        -         -  $(127,576) $(127,576)
                           ----------- -------- ---------- ---------- ----------

Balance 10/31/01            27,000,000 $108,000 $ (88,000) $(127,576) $(107,576)


Net Loss                             -        -         -    (86,400)   (86,400)
                           ----------- -------- ---------- ---------- ----------
Balance at 10/31/02
                            27,000,000  108,000   (88,000)  (213,976)  (193,976)


Net Loss                             -        -         -   (131,000)  (131,000)


Merger with TPII             5,108,957   20,436  (141,288)         -   (120,852)
Sale of common stock
for cash                       440,000    1,760     42,240         -     44,000
                           ----------- -------- ---------- ---------- ----------

Balance at 7/31/03         $32,548,957 $130,196 ($187,048) ($344,976) ($401,828)
                           =========== ======== ========== ========== ==========








           See accompanying notes to condensed financial statements.

                                       5

<PAGE>




                                                  Nine       Nine      July 24,
                                                 months     months       2001
                                                  ended     ended    (Inception)
                                                 July 31,  July 31,  to July 31,
                                                   2003      2003       2003
                                                ---------- --------- -----------

OPERATING ACTIVITIES
 Net (loss)                                     $(131,000) $(70,004)   (344,976)
                                                ---------- --------- -----------
 Adjustments to reconcile net loss to net cash
  used in operating activities:
    Depreciation and amortization                     939       932       2,597
 Changes in operating assets and liabilities:
    Increase in other assets                         (702)               (2,523)
    Increase (decrease) in accounts payable
     and accrued liabilities                       97,120   (16,417)    115,909
                                                ---------- --------- -----------
    Total adjustments                              97,357   (15,485)    115,983
                                                ---------- --------- -----------
       Net cash used in operating activities
                                                  (33,643)  (85,489)   (228,993)
                                                ---------- --------- -----------
INVESTING ACTIVITIES
 Purchase of property and equipment                  (130)               (3,860)
 Investment in related companies                  (10,000)              (10,000)
                                                ---------- --------- -----------
       Net cash provided by (used in)
        investing activities                      (10,130)        -     (13,860)
                                                ---------- --------- -----------

FINANCING ACTIVITIES
 Proceeds from note payable                         4,532    84,934     183,612
 Proceeds from issuance of common stock            44,000                64,000
                                                ---------- --------- -----------

Net cash provided by financing activities          48,532    84,934     247,612
                                                ---------- --------- -----------


Net increase (decrease) in cash                     4,759      (555)      4,759


Cash at beginning of period                             -       555           -
                                                ---------- --------- -----------


Cash at end of period                           $   4,759  $     (0) $    4,759
                                                ========== ========= ===========


       Supplemental disclosures of cash flow
       information:
         Cash paid during the period for interest                    $        -

       Supplemental disclosures of non-cash
       investing and financing activities:
          Assumption of Liabilities of Transform
          Pack International, Inc.              $ 120,852            $  120,852





            See accompanying notes to condensed financial statements.

                                       6

<PAGE>


TRANSFORM PACK INTERNATIONAL, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED)
JULY 31, 2003


NOTE 1:  DESCRIPTION OF COMPANY

On May 28, 2003, Transform Pack International,  Inc. (the "Company") merged with
Quantum HIPAA Consulting,  Inc (Quantum"). The merger with Quantum was accounted
for as a  non-operating  public  company.  The  Company is a  development  stage
enterprise which will provide medical  practice and HIPAA compliance  consulting
services to the health care industry. (See Note 4)

The accompanying condensed financial statements reflect ongoing losses, negative
cash flows from operating activities, negative working capital and shareholders'
deficit.

The Company has no revenues to date.  Since its inception,  the Company has been
dependent  upon  the  receipt  of  capital  investment  to fund  its  continuing
activities.  In  addition to the normal  risks  associated  with a new  business
venture,  there can be no assurance  that the  Company's  business  plan will be
successfully  executed. The Company's ability to execute its business model will
depend on its ability to obtain  additional  financing  and achieve a profitable
level of operations. There can be no assurance that sufficient financing will be
obtained.  Nor  can any  assurance  be  made  that  the  Company  will  generate
substantial   revenues  or  that  the  business  operations  will  prove  to  be
profitable. These conditions raise substantial doubt about the Company's ability
to continue as a going  concern.  The  financial  statements  do not include any
adjustments that might result from the outcome of these uncertainties.


NOTE 2:  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Property and Equipment

Furniture and equipment are stated at cost. Depreciation is calculated using the
straight-line  method over the estimated useful lives of the assets, which range
from three to five years.

Research and Development Costs

Research and development costs are charged to expense when incurred.

Use of Estimates

The preparation of financial  statements in conformity  with generally  accepted
accounting principles requires management to make estimates and assumptions that
affect  the  reported  amounts  of assets  and  liabilities  and  disclosure  of
contingent  assets and  liabilities at the date of the financial  statements and
the reported amount of revenues and expenses during the reporting period. Actual
results could differ from those estimates and the differences could be material.

                                       7

<PAGE>


TRANSFORM PACK INTERNATIONAL, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED)
JULY 31, 2003


NOTE 2:  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Income Taxes

The  Company  has  not  recognized  any  benefit  of  such  net  operation  loss
carryforwards  in the accompanying  financial  statements in accordance with the
provisions of SFAS No. 109, as the  realization  of this deferred tax benefit is
not likely. A 100% valuation  allowance has been recognized to offset the entire
effect of the Company's net deferred tax asset.

Recent Accounting Pronouncements

In June 2001, the Financial Accounting Standards Board ("FASB") issued Statement
of Financial  Accounting Standards (" SFAS ') No. 143 which requires entities to
record the fair value of a liability for an asset  retirement  obligation in the
period in which it is incurred  and a  corresponding  increase  in the  carrying
amount of the related long-lived asset. Subsequently,  the asset retirement cost
should be allocated to expense using a systematic  and rational  method over its
useful life. SFAS No. 143 is effective for fiscal years beginning after June 15,
2002.  Adoption of SFAS No. 143 did not have a material  impact on the Company's
financial statements.

In June 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with
Exit or Disposal  Activities.  This statement addresses accounting and reporting
for costs  associated  with exit or disposal  activities and nullifies  emerging
issues  Task Force  Issue No.  94-3.  The  statement  is  effective  for exit or
disposal  costs  initiated  after  December  31,  2002,  with early  application
encouraged.  The Company adopted SFAS No. 146 effective  January 1, 2003,  which
did not have a material impact on the Company's financial statements.

In December  2002,  the FASB issued SFAS No.  148,  Accounting  for  Stock-Based
Compensation-Transition  and Disclosure-an  amendment of FASB Statement No. 123.
This statement provides alternative methods of transition for a voluntary change
to  the  fair  value  based  method  of  accounting  for  stock-based   employee
compensation.  Adoption  of SFAS No. 14 8 did not have a material  impact on the
Company's financial statements.

                                       8

<PAGE>


TRANSFORM PACK INTERNATIONAL, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED)
JULY 31, 2003


NOTE 2:  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

In May 2003,  the FASB issued SFAS No. 150,  "Accounting  For Certain  Financial
Instruments with  Characteristics of both Liabilities and Equity".  SFAS No. 150
changes the accounting for certain financial instruments with characteristics of
both liabilities and equity that, under previous  pronouncements,  issuers could
account for as equity.  The new  accounting  guidance  contained in SFAS No. 150
requires that those  instruments  be classified  as  liabilities  in the balance
sheet.  SFAS  No.  150  affects  the  issuer's  accounting  for  three  types of
freestanding  financial  instruments.  One type is mandatory  redeemable shares,
which the issuing company is obligated to buy back in exchange for cash or other
assets. A second type includes put options and forward purchase contracts, which
involve  instruments  that do or may  require the issuer to buy back some of its
shares in exchange for cash or other assets.  The third type of instruments that
are  liabilities  under this Statement is  obligations  that can be settled with
shares,  the monetary value of which is fixed, tied solely or predominantly to a
variable  such as a market  index,  or  varies  inversely  with the value of the
issuers' shares. SFAS No. 150 does not apply to features embedded in a financial
instrument  that is not a derivative in its entirety.  Most of the provisions of
SFAS No. 150 are consistent with the existing  definition of liabilities in FASB
Concepts  Statement  No. 6,  "Elements of Financial  Statements".  The remaining
provisions of this Statement are consistent  with the FASB's  proposal to revise
that definition to encompass certain  obligations that a reporting entity can or
must settle by issuing its own shares.  This  Statement  shall be effective  for
financial  instruments entered into or modified after May 31, 2003 and otherwise
shall be effective at the beginning of the first interim period  beginning after
June 15,  2003,  except for  mandatory  redeemable  financial  instruments  of a
non-public  entity,  as to  which  the  effective  date  is for  fiscal  periods
beginning after December 15, 2003. The Company is currently assessing the impact
of SFAS  No.  150,  which  is not  expected  to have a  material  impact  on the
Company's financial statements.


NOTE 3:  BASIS OF PRESENTATION FOR INTERIM FINANCIAL INFORMATION

The accompanying  unaudited condensed financial statements have been prepared in
accordance with generally accepted accounting principles for interim information
and with the instructions for Form 10-QSB and Article 10 of Regulation SB of the
Securities  and  Exchange  Commission  rules  and  do  not  include  all  of the
information and footnotes required by accounting  principles  generally accepted
in the United  States of  America  for  complete  financial  statements.  In the
opinion  of  management,   all  adjustments   consisting  of  normal   recurring
adjustments,  considered  necessary for a fair  presentation have been included.
Operating results for any quarter are not necessarily  indicative of the results
for any other quarter or for the full year.

It is recommend that the accompanying  condensed financial statements be read in
conjunction  with the financial  statements and notes for the year ended October
31, 2002, found in the Company's Form 8-K

                                       9

<PAGE>

TRANSFORM PACK INTERNATIONAL, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED)
JULY 31, 2003

NOTE 4: MERGER WITH QUANTUM HIPAA CONSULTING, INC.

Effective May 28, 2003,  the Company  consummated a merger  pursuant to a merger
agreement with Quantum HIPAA  Consulting,  Inc.  Quantum HIPAA  Consulting,  Inc
developed  a training  compact  disc and  manuals  to  instruct  the  healthcare
industry on the  implementation  of the  regulations  created to comply with the
Health Insurance Portability and Accountability Act of 1996 (HIPAA).

The Company completed the merger by issuing  27,000,000 million shares of Common
Stock to the sole  shareholder  of Quantum,  in exchange  for all the issued and
outstanding shares of Quantum. For accounting purposes,  the acquisition will be
treated as a recapitalization of the Company. The value of the net assets of the
Company after the  acquisition  was completed is the same as their historic book
value.

On May 30 2003, in accordance  with the  agreement,  the Company sold its wholly
owned  subsidiary,  Transform Pack, Inc. (TPI) to certain previous  shareholders
and investors of the Company.  Transform  Pack, Inc. and its  shareholders  have
agreed to assume  and  indemnify  the  Company  for all  operating  debts of the
Company.

NOTE 5: OTHER COMMON STOCK TRANSACTIONS

In July 2003,  the  company  sold  440,000  shares of common  stock and  220,000
warrants  with  exercise  price of $.25 per share and 220,000  warrants  with an
exercise  price of $.40 per share for  $44,000.  The  warrants  are  exercisable
anytime before 5:00 pm March 31, 2006.

NOTE 6: RELATED PARTY TRANSACTIONS

On November 1, 2002, the Company entered into an agreement with a shareholder to
purchase certain  intellectual  property integral to the Company's business.  In
exchange, the company issued a three (3) year installment note for $179,080 with
an interest rate of eighteen  percent (18%) per annum. The price of the sale was
equal to the cost the  shareholder  incurred to develop the property  purchased.
The note is payable monthly  starting  January 2003. The Company is in technical
default as no  payments  have been made on the note.  The  Company  is  accruing
interest,  at 18% per annum,  monthly on the unpaid  principal  balance  and has
classified the note as current as per the agreement.

On November 2, 2002 the Company  signed a demand note,  with an interest rate of
eighteen  percent (18%) per annum, for the expenses a shareholder paid on behalf
of the Company subsequent to the sale of the intellectual  property. The current
note balance is $4,532

In July 2003, the Company purchased a 20% interest  Renaissance  Health Systems,
Inc. for $5,000 from a shareholder of the Company. Renaissance Health Systems is
a development  stage enterprise in the health care business.  Additionally,  the
Company  purchased a 20%  interest in Quantum  Medical  Technologies,  Inc.  for
$5,000 from a shareholder of the Company. Quantum Medical Technologies,  Inc. is
a development stage enterprise in the medical technologies business.

                                       10

<PAGE>


ITEM 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.

General

The discussion  and analysis set forth below should be read in conjunction  with
our Financial  Statements and the related notes thereto  appearing  elsewhere in
this quarterly report. The information  presented for the nine months ended July
31, 2003 and July 31, 2002,  was derived from  unaudited  financial  statements,
which,  in our  opinion,  reflect  all  adjustments  (consisting  only of normal
recurring adjustments) necessary for a fair presentation.

Forward Looking Statements

This Report on Form 10-QSB contains  certain  forward-looking  statements.  When
used in this report,  press  releases and  elsewhere  by the  management  of the
Company from time to time, the words  "believes",  "anticipates",  and "expects"
and similar expressions are intended to identify forward-looking statements that
involve  certain  risks  and  uncertainties.  Additionally,  certain  statements
contained  in this  discussion  may be deemed  forward-looking  statements  that
involve a number of risks and uncertainties.  Among the factors that could cause
actual  results  to differ  materially  are the  following:  the  ability of the
Company to meet its working  capital and liquidity  needs,  economic  trends for
consumer  advertisers,  the  availability  of  long-term  credit,  unanticipated
changes in the U.S. and international economies,  business conditions and growth
in e-commerce and the timely  development  and  acceptance of new products,  the
impact of competitive  products and pricing,  and other risks detailed from time
to time in the Company's  SEC reports.  Readers are cautioned not to place undue
reliance on these  forward-looking  statements,  which speak only as of the date
hereof.  The Company undertakes no obligation to publicly release the results of
any events or  circumstances  after the date hereof or to reflect the occurrence
of unanticipated events.

Going Concern

The  Company is a  development  stage  company  that over the last two years has
expensed material sums in creating procedures, manuals and systems to assist the
medical  community  in the  implementation  of medical  regulations.  Though the
Company has materially  finished  developing its training  programs,  additional
updates and deployment will be required.

As shown in the accompanying condensed  consolidated  financial statements,  the
Company  has  incurred  recurring  losses  and  negative  cash  flows  from  its
development  and  organization  activities and has negative  working capital and
shareholders'   deficit.   Under  normal  conditions,   these  conditions  raise
substantial doubt about the Company's ability to continue as a going concern.

There  can be no  assurance  that  the  Company  will be  able  to  successfully
implement  its  plans  to  generate   additional  investor  interest  and  raise
additional  capital,  or if such plans are  successfully  implemented,  that the
Company will achieve its goals.

Furthermore,  if the  Company  is unable to raise  additional  funds,  it may be
required  to modify its growth and  developmental  plans,  and even be forced to
severely limit development operations completely.

                                       11

<PAGE>

The accompanying  condensed consolidated financial statements have been prepared
assuming  that the Company will  continue as a going  concern and do not include
any adjustments to reflect the possible future effects of the recoverability and
classification  of assets or the amounts and  classification of liabilities that
might result from the outcome of this  uncertainty.  See  "Liquidity and Capital
Resources," below.


Results of Operations

Three months ended July 31, 2003 and 2002

The  expenses  for the  quarter  ended July 31, 2003 were $71,  569  compared to
$21,870 for the quarter July 31, 2002.  The  increase  was  primarily  due to an
increase in salaries and consulting fees.

Nine months ended July 31, 2003 and 2002

The expenses for the nine months ended July 31, 2003 were  $131,000  compared to
$70,004 for the nine months ended July 31, 2002.  The increase was primarily due
to an  increase in  salaries  and  interest  expense.  The  increase in interest
expense  generated  from the  installment  note  issued for the  acquisition  of
certain intellectual property integral to the Company's business.

Liquidity and Capital Resources

At July 31,  2003,  the  Company  had  working  capital  deficit of  $415,614 as
compared to a working capital deficit of $179,400 at July 31, 2002.

Cash inflow from financing activities was $48,532 for the nine months ended July
31, 2003, compared $84,934 for the nine months ended July 31, 2002. The decrease
was due to a reduction in funds advanced by the majority shareholder.

The  Company's  development  plan is to  identify,  negotiate  with and  acquire
business  and  services  that will allow the  Company  to provide  comprehensive
consulting services, technological, strategic intelligence and systems that will
allow the small to medium size  medical  organization  to provide  better  care,
better medical outcomes and earn more profit.  The Company expect to acquire the
candidate  businesses  after  extensive due  diligence,  and then to acquire the
business  enterprise  including cash flow by issuing stock,  notes and cash. The
Company expects to secure financing for the acquisition by selling common and/or
preferred  shares,  issuing  debt  or  notes  and by  leveraging  the  potential
acquisition.  There is no assurance that the  Company will be able to execute on
its plans and  clearly  additional  financing  will be  needed  to  develop  and
implement its business plan.


                                       12

<PAGE>


ITEM 3. CONTROLS AND PROCEDURES

Our Management,  which includes only one officer acting as both CEO and our CFO,
has conducted an evaluation of the effectiveness of our disclosure  controls and
procedures  (as defined in Rule  13a-15(e) and 15d-15(e)  promulgated  under the
Securities  and  Exchange  Act of 1934,  as amended) as of the end of the fiscal
quarter covered by this report.  Based upon that evaluation and both our limited
developmental  history as well as the size of our  organization,  our management
has concluded that we have adequate disclosure controls. However we must improve
procedures  for effective and timely  gathering,  analyzing and  disclosing  the
information  we  are  required  to  disclose  in our  reports  filed  under  the
Securities  Exchange  Act  of  1934,  as  amended.  Management  expects  to  add
additional  controls  and  personnel  in the  near  future  as  capital  becomes
available.  There have been no significant changes made in our internal controls
or in other factors that could significantly affect our internal controls during
the fiscal quarter covered by this report.


                                     PART II
                                OTHER INFORMATION


Item 1.  Legal Proceedings

The Company is not a party to any litigation.

Item 2.  Changes in Securities

None

Item 3.  Defaults Upon Senior Securities

As of June 30, 2003, the Company is in default of a $ 179,080  obligation to the
Company's  President  and largest  shareholder.  He has not declared the note in
default as of this time.

Item 4.  Submission of Matters to a Vote of Security-Holders

None

Item 5.  Other Information

On September 3, 2003, Ms. Nathalie Cormier, a director of the company,  resigned
as a director.

The Company expects to submit in the near future to the shareholders for a vote,
the  reincorporation  of the Company in Nevada.  This will change the  Company's
name and stock symbol members and affect a reverse stock split.

Item 6.  Exhibits and Reports on Form 8-K.

Reports on Form 8-K:

                                       13

<PAGE>

On or about  June 11,  2003,  the  Company  filed a report  on Form 8-K with the
Securities  and Exchange  Commission  reporting  under Items 1 and 2 a change in
control,  the acquisition of Quantum HIPAA Consulting Group,  Inc., and the sale
of a subsidiary.

On August 29, 2003,  the Company filed a report on Form 8-K with the  Securities
and  Exchange  Commission  reporting  under  Item 8 a change in  fiscal  year to
October 31.

Exhibits:  Copies of the  following  documents  are  included  or  furnished  as
exhibits to this report pursuant to Item 601 of Regulation S-B.

 Exhibit      SEC Ref.     Title of Document
   No.           No.

   31.1          31        Certification of the Chief Executive Officer and
                           Chief Financial Officer pursuant to Section 302 of
                           the Sarbanes-Oxley Act of 2002

   32.1          32        Certifications of the Chief Executive Officer and
                           Chief Financial Officer pursuant to Section 906 of
                           the Sarbanes-Oxley Act of 2002



SIGNATURE

In accordance with the requirements of the Securities  Exchange Act of 1934, the
Registrant has caused this report to be signed on its behalf by the undersigned,
duly authorized.

                            TRANSFORM PACK INTERNATIONAL, INC.


Date: September 22, 2003

                                    /S/ Noel J. Guillama
                            BY: _____________________________________

                                    Noel J. Guillama, President

                                       14